A 26-Week Randomized Controlled Trial of Semaglutide Once Daily Versus Liraglutide and Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise With or Without Metformin.
Ildiko LingvayCyrus V DesouzaKatarina S LalicLudger RoseThomas HansenJeppe ZachoThomas R PieberPublished in: Diabetes care (2018)
Once-daily semaglutide at doses up to 0.3 mg/day resulted in greater reductions in HbA1c compared with liraglutide or placebo but with a higher frequency of GI AEs.